Alan Fuhrman - 27 Oct 2021 Form 4 Insider Report for Checkmate Pharmaceuticals, Inc.

Role
Interim President and Chief Executive Officer, Director
Signature
/s/ Kleem Chaudhary, attorney-in-fact
Issuer symbol
N/A
Transactions as of
27 Oct 2021
Net transactions value
$0
Form type
4
Filing time
29 Oct 2021, 18:54:45 UTC
Previous filing
21 Jun 2021
Next filing
20 May 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMPI Stock Option (Right to Buy) Award $0 +246,671 $0.000000 246,671 27 Oct 2021 Common Stock 246,671 $3.93 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest in 12 equal monthly installments, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Interim President and Chief Executive Officer